Listen: The Cost Of PrEP, The HIV Prevention Pill
( function() {
var func = function() {
var iframe = document.getElementById(‘wpcom-iframe-ee2dde120c20ff9a07f81293a6bc3375’)
if ( iframe ) {
iframe.onload = function() {
iframe.contentWindow.postMessage( {
‘msg_type’: ‘poll_size’,
‘frame_id’: ‘wpcom-iframe-ee2dde120c20ff9a07f81293a6bc3375’
}, “https://embeds.kff.org” );
}
}
// Autosize iframe
var funcSizeResponse = function( e ) {
var origin = document.createElement( ‘a’ );
origin.href = e.origin;
// Verify message origin
if ( ’embeds.kff.org’ !== origin.host )
return;
// Verify message is in a format we expect
if ( ‘object’ !== typeof e.data || undefined === e.data.msg_type )
return;
switch ( e.data.msg_type ) {
case ‘poll_size:response’:
var iframe = document.getElementById( e.data._request.frame_id );
if ( iframe && ” === iframe.width )
iframe.width = ‘100%’;
if ( iframe && ” === iframe.height )
iframe.height = parseInt( e.data.height );
return;
default:
return;
}
}
if ( ‘function’ === typeof window.addEventListener ) {
window.addEventListener( ‘message’, funcSizeResponse, false );
} else if ( ‘function’ === typeof window.attachEvent ) {
window.attachEvent( ‘onmessage’, funcSizeResponse );
}
}
if (document.readyState === ‘complete’) { func.apply(); /* compat for infinite scroll */ }
else if ( document.addEventListener ) { document.addEventListener( ‘DOMContentLoaded’, func, false ); }
else if ( document.attachEvent ) { document.attachEvent( ‘onreadystatechange’, func ); }
} )();
Can’t see the audio player? Click here to listen.
KHN correspondent Shefali Luthra joined a discussion on the Vox podcast “Today, Explained” about the cost dynamics surrounding pre-exposure prophylaxis, or PrEP, a game-changing drug that prevents the transmission of HIV.
Gilead Sciences — the manufacturer of the brand-name versions of this preventive medicine, such as Truvada and Descovy — seeks to extend its patent but faces pushback from federal lawmakers, including Sen. Bernie Sanders (I-Vt.) and Rep. Alexandria Ocasio-Cortez (D-N.Y.).
Luthra has reported on how public health officials whose efforts to increase access to the HIV prevention pill for those at risk have faced roadblocks: the drug’s price tag, which has surged in recent years, and changes in insurance coverage that put a heftier financial burden on patients.